Osimertinib as first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC): Final efficacy and safety results from two phase I expansion cohorts.

Yang, J C-H; Ramalingam, S S; Lee, C K; Kurata, T; Kim, D-W; John, Thomas; Nogami, N; Ohe, Y; Rukazenkov, Y; Murphy, M; Jänne, P A

doi:10.1093/annonc/mdz063.020

Austin Health

Title

Osimertinib as first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC): Final efficacy and safety results from two phase I expansion cohorts.

Publication Date

2019-04

Author(s)

Yang, J C-H

Ramalingam, S S

Lee, C K

Kurata, T

Kim, D-W

John, Thomas

Nogami, N

Ohe, Y

Rukazenkov, Y

Murphy, M

Jänne, P A

Type of document

Journal Article

DOI

10.1093/annonc/mdz063.020

Link

link

Citation

Annals of oncology : official journal of the European Society for Medical Oncology 2019; 30 Suppl 2: ii48

Jornal Title

Annals of oncology : official journal of the European Society for Medical Oncology

Files:

Name	Size	format	Description	Link